Featured Press Release

  • 11/8/17 6:50 am EST

    -- Bendeka market share of 97% with record royalty revenue of $41.4 million --

    -- Revenue grows 67% year-over-year to $63.0 million --

    -- New patent related to RYANODEX granted --

    -- Tentative FDA approval for PEMFEXY (pemetrexed injection) --

    -- Net income was $0.98 per diluted share and Adjusted Non-GAAP net income was $1.22 per diluted share --

    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq: EGRX) today announced its financial results for the three- and nine-months ended September 30, 2017. Highlights of and subsequent to the third quarter of 2017 include: Financial Highlights: Total revenue for the third quarter of 2017 grew 67% to $63.0 million compared to $37.8 million in the third quarter of 2016; Royaltymore